Tango Therapeutics
Staff Accountant
Boston, MA | $68K - $203K
Qualifications
- A minimum of a bachelor’s degree in accounting or related field is required
- Minimum of 1 year of experience in accounting/finance is required
- Excellent verbal and written communication skills
- Excellent organizational skills and attention to detail
- Understanding of and the ability to adhere to generally accepted accounting principles
- Proficiency in Microsoft Office (specifically Excel) is required
- Ability to work independently and within a team environment is important
Responsibilities
- Reporting to the Manager of Accounting, this individual will be a critical and core member of the growing accounting and finance team and will partner with the Senior Accountant, Controller and VP of Finance to help scale the finance function as the company continues to grow
- Prepare monthly account reconciliations
- Assists with the preparation of period end financial statements
- Prepare and record journal entries to the general ledger
- Assist with the period close process, including performance and documentation of internal controls
- Continuously monitor the AP inbox and support the weekly payment run
- Support various system maintenance and potential future system implementations
- Help to prepare documentation for external auditors’ requests
- Assist with compiling tax workpaper support for tax provisions and annual tax returns
- Support the Finance team with various ad-hoc requests and projects as needed
- Maintain effective relationships with other departments to ensure effective and efficient cross-functional collaboration
- Specific areas of responsibilities may include, but are not limited to cash, prepaid expenses, fixed assets, accounts payable, accrued expenses and payroll
- Maintains knowledge of acceptable accounting practices and procedures
- 51-200 employees
- Biotechnology, Pharmaceuticals, Healthcare Services, Healthcare, Medical Research, Drug Discovery, Precision Medicine
- Public Company
- Last round: Post IPO equity
- Last round: US$ 186.0M
- Boston, Massachusetts
- Company Specialties:
cancer, pharmaceutical research, functional genomics, drug discovery, and synthetic lethality
Company information
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
